Adding SolpaOne to your pain management toolkit
ADDING SOLPAONE TO YOUR
PAIN MANAGEMENT TOOLKIT
SolpaOne is a paracetamol-based product that can be used for the short-term treatment of mild to moderate pain and/or fever.
It is suitable for adults and adolescents from 16 years who weigh more than 50kg.4 Those weighing less than 50kg (around 8 stone) may need a lower dose of paracetamol.3,4
SolpaOne effervescent tablet should be placed in a full glass of water and completely dissolved before swallowing.4
Ensure that your customer understands that the dosing instructions for SolpaOne are different to what they may have been used to with other paracetamol products:
SolpaOne41000mg paracetamol |
Other |
|
|---|---|---|
| DOSE | 1 tablet | 1-2 tablets |
| FREQUENCY | Every 6 hours | Every 4-6 hours |
| MAXIMUM DOSE IN 24 HOURS |
4 tablets (4g of paracetamol) |
8 tablets (4g of paracetamol) |
WHO IS SOLPAONE IDEAL FOR?
THOSE WITH SWALLOWING DIFFICULTIES
Some degree of difficulty swallowing solid oral dosage forms is reported in around 15–20% of adults without dysphagia9 (dysphagia refers to difficulty swallowing caused by medication or associated with another condition, e.g. a stroke)10
SolpaOne contains the maximum dose in a single tablet so just one tablet needs to be dissolved
It is rapidly absorbed4
THOSE TAKING MULTIPLE MEDICATIONS
Simple, easy to remember one-tablet dose to help aid compliance
Can be taken with most prescription medicines, including most antibiotics4
SolpaOne is safe for women using contraceptives3
THOSE WITH ACUTE HEADACHE OR BACK PAIN
SolpaOne gets to work up to 2x faster* than regular paracetamol tablets4
It provides the maximum strength in one single tablet†
It is gentle on the stomach and can be taken on an empty stomach3
*Based on absorption data
†1 tablet = 1 dose (take only one tablet at a time)
THOSE WITH EVERYDAY PAIN AND FEVER ASSOCIATED WITH COLDS, FLU AND SORE THROATS
SolpaOne comes in an easy-to-swallow effervescent format
It has to be dissolved in water. Drinking plenty of water is recommended for those with a high temperature or cold and flu symptoms to avoid dehydration6-8
THOSE WITH SWALLOWING DIFFICULTIES
Some degree of difficulty swallowing solid oral dosage forms is reported in around 15–20% of adults without dysphagia9 (dysphagia refers to difficulty swallowing caused by medication or associated with another condition, e.g. a stroke)10
SolpaOne contains the maximum dose in a single tablet so just one tablet needs to be dissolved
It is rapidly absorbed4
THOSE TAKING MULTIPLE MEDICATIONS
Simple, easy to remember one-tablet dose to help aid compliance
Can be taken with most prescription medicines, including most antibiotics4
SolpaOne is safe for women using contraceptives3
THOSE WITH ACUTE HEADACHE OR BACK PAIN
SolpaOne gets to work up to 2x faster* than regular paracetamol tablets4
It provides the maximum strength in one single tablet†
It is gentle on the stomach and can be taken on an empty stomach3
*Based on absorption data
†1 tablet = 1 dose (take only one tablet at a time)
THOSE WITH EVERYDAY PAIN AND FEVER ASSOCIATED WITH COLDS, FLU AND SORE THROATS
SolpaOne comes in an easy-to-swallow effervescent format
It has to be dissolved in water. Drinking plenty of water is recommended for those with a high temperature or cold and flu symptoms to avoid dehydration6-8
RECOMMENDING SOLPAONE
SolpaOne may not be suitable for everyone and some customers should be referred to the pharmacist or their doctor.3,4
Those weighing less than 50kg (around 8 stone)
Those who have had an allergic reaction to paracetamol or any of the ingredients in SolpaOne
Those with liver or kidney problems, Gilbert's syndrome, haemolytic aenemia or an enzyme deficiency
Customers suffering from dehydration or chronic malnutrition
Elderly patients who are frail and immobile
Anyone who regularly drinks more than the maximum amount of alcohol recommended (14 units a week)
Asthmatic patients who are sensitive to aspirin
Those on medicines to thin the blood or certain medicines to treat sickness, high cholesterol, gout, epilepsy, tuberculosis and certain infections
SODIUM AND FLUID RESTRICTIONS
Customers on a sodium-restricted diet may not be able to take effervescent paracetamol tablets. However, each SolpaOne tablet contains just over a quarter of the daily recommended intake of sodium,4 so it may be a more sodium conscious option for customers who currently take 2 effervescent paracetamol tablets.
Customers on a fluid-restricted diet, e.g. those with heart failure or renal failure, will have limits on the amount of fluid they are allowed to consume each day. Effervescent tablets may not be appropriate for them2 due to the amount of liquid required to dissolve the tablets.
As with all other paracetamol products, advise your customer that they should not take any other products containing paracetamol while taking SolpaOne. Also remind them to talk to a doctor at once if they take too much SolpaOne, even if they are feeling well.3,4
Customers should talk to their doctor if they
do not feel better or if they feel worse after 3 days.11
1. Ayoub, SS. Paracetamol (acetaminophen): A familiar drug with an unexplained mechanism of action. Temperature. 2021; 8(4):351–371.
https://doi.org/10.1080/23328940.2021.1886392
2. NICE. Analgesia – mild-to-moderate pain. 2021. [Online.] https://cks.nice.org.uk/topics/analgesia-mild-to-moderate-pain/
3. NHS. Paracetamol for adults. 2022. [Online.] https://www.nhs.uk/medicines/paracetamol-for-adults/
4. MHRA. SolpaOne. SmPC. 2024. [Online.] https://mhraproducts4853.blob.core.windows.net/docs/0fa5f0aaeab6197db9e35e4f460b88b21e36e654
5. BNF. Paracetamol. 2024. https://bnf.nice.org.uk/drugs/paracetamol/
6. NHS. High temperature (fever) in adults. 2023. https://www.nhs.uk/conditions/fever-in-adults/
7. NHS. Common cold. 2024. https://www.nhs.uk/conditions/common-cold/
8. NHS. Flu. 2023. https://www.nhs.uk/conditions/flu/
9. Radhakrishnan, C. et al. A difficult pill to swallow: an investigation of the factors associated with medication swallowing difficulties Patient Preference and Adherence. 2021; 15:29-40. https://doi.org/10.2147/PPA.S277238
10. NHS. Dysphagia (swallowing problems). 2023. [Online.] https://www.nhs.uk/conditions/swallowing-problems-dysphagia/
11. MHRA. SolpaOne. PIL. 2022. https://mhraproducts4853.blob.core.windows.net/docs/73a25923c730e6f1de5763a9d1b6c37ba28ef9df
Online sources last accessed January 2025
SolpaOne 1000 mg Effervescent Tablets (P) contain paracetamol. For short term symptomatic treatment of mild to moderate pain and/or fever. Adults and children over 16 years and weighing over 50 kg: 1 tablet dissolved in water every 6 hours as needed. Max 4 tablets in 24 hours. Do not use in children under 16 years and weighing less than 50 kg. Do not take with other paracetamol-containing products. In case of overdose, seek immediate medical advice, even if the patient feels well. Contraindications: known hypersensitivity to the ingredients. Caution: renal or hepatic impairment, chronic alcoholism, non-cirrhotic alcoholic liver disease, Gilbert’s syndrome, haemolytic anaemia, dehydration or chronic malnutrition, glucose-6-phosphate dehydrogenase deficiency, paracetamol can interfere with laboratory tests. Product contains sodium (1 tablet equivalent to 26.68% recommended daily intake) and sorbitol. Interactions: probenecid, cholestyramine, rifampicin, carbamazepine, phenytoin, phenobarbital, primidone, warfarin and other coumarins, salicylamide, metoclopramide, domperidone, isoniazid, flucloxacillin, St John’s wort, and chloramphenicol. Side effects: hypersensitivity reaction, angioedema, anaphylactic shock, aspirin-sensitive bronchospasm, platelet disorders, stem cell disorders, thrombocytopenia, leukopenia, haemolytic anaemia, pancytopenia, methaemoglobinaemia, agranulocytosis, hepatic failure, hepatic necrosis, hepatitis, severe renal impairment, gastrointestinal haemorrhage, hypoglycaemia, Interstitial nephritis and serious skin reactions. PL 36390/0411. MAH: Cipla (EU) Limited Dixcart House, Addlestone Road, Bourne Business Park, Addlestone, Surrey, KT15 2LE, UK. Date of preparation: 06/2023. RRP (ex. VAT): 12s £5.19.
SPC: https://mhraproducts4853.blob.core.windows.net/docs/0fa5f0aaeab6197db9e35e4f460b88b21e36e654
Adverse event reporting
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow card scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or the Apple App Store.